Menu
Search
|

Menu

Close
X

ZIOPHARM Oncology Inc ZIOP.OQ (NASDAQ Stock Exchange Capital Market)

3.75 USD
+0.02 (+0.54%)
As of 12:33 AM IST
chart
Previous Close 3.73
Open 3.78
Volume 145,908
3m Avg Volume 393,734
Today’s High 3.87
Today’s Low 3.69
52 Week High 7.88
52 Week Low 3.33
Shares Outstanding (mil) 141.96
Market Capitalization (mil) 890.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
5
FY16
7
FY15
4
EPS (USD)
FY17
-0.406
FY16
-1.322
FY15
-1.013
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
139.32
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-45.27
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Laurence Cooper
Chief Executive Officer, Since 2015
Salary: $500,000.00
Bonus: $700,000.00
Kevin Lafond
Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer, Since 2013
Salary: $245,000.00
Bonus: $51,450.00
David Mauney
Interim Chief Operating Officer, Executive Vice President, Chief Business Officer, Since 2017
Salary: --
Bonus: --
Caesar Belbel
, Since
Salary: $375,000.00
Bonus: $262,500.00
Francois Lebel
Executive Vice President - Research and Development and Chief Medical Officer, Since 2015
Salary: $410,000.00
Bonus: $114,800.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One First Avenue Parris Building
, Navy Yard Plaza
BOSTON   MA   02129

Phone: +1617.2591970

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

SPONSORED STORIES